InterPAD - DETAILS

dactolisib, 915019-65-7, NVP-BEZ235, BEZ235, NVP-BEZ 235, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile, BEZ-235, NVPBEZ235, BEZ 235, NVP-BEZ-235, NVP BEZ235, BEZ235 (NVP-BEZ235, Dactolisib), RTB101, RTB-101, RUJ6Z9Y0DT, NSC-751249, CHEBI:71952, 915019-65-7 (free base), 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, S1009, 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile, BEZ235 (NVP-BEZ235), NVP-BEZ235-NX, 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile., 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile, Dactolisib [USAN], Dactolisib [USAN:INN], UNII-RUJ6Z9Y0DT, 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile, Kinome_2911, CT-BEZ, Dactolisib (BEZ235), Dactolisib; BEZ-235, DACTOLISIB [INN], Dactolisib (USAN/INN), Nvp-bez235, free base, mTOR Inhibitor, BEZ235, DACTOLISIB [WHO-DD], NVP-BEZ235?, SCHEMBL143623, GTPL7950, CHEMBL1879463, BDBM92862, AMY2877, DTXSID10238599, EX-A404, BCPP000344, HMS3244G21, HMS3244G22, HMS3244H21, HMS3672E19, BCP00216, MFCD10565944, NSC751249, NSC755807, NSC800085, AKOS005217097, BCP9000397, CCG-207981, CS-0080, DB11651, ES-0038, NSC 751249, NSC-755807, NSC-800085, PB26555, 2-methyl-2-[3-methyl-2-oxo-8-(3-quinolinyl)-1-imidazo[4,5-c]quinolinyl]propanenitrile, Dactolisib (BEZ235, NVP-BEZ235), NCGC00187481-01, NCGC00187481-02, NCGC00187481-04, NCGC00187481-05, NCGC00187481-06, NCGC00187481-15, 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile, 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, AC-25486, HY-50673, FT-0658563, NS00071714, BEZ235 , NVP-BEZ235, EN300-60135, D10552, J-509915, Q4835503, BRD-K12184916-001-01-4, Z329731510, 1028385-31-0, 2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl)propionitrile, 2-Methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile, 2-methyl-2-[4-[3-methyl-2-oxo-8-(3-quinolyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile, 2-METHYL-2-{4-[3-METHYL-2-OXO-8-(QUINOLIN-3-YL)-1H,2H,3H-IMIDAZO[4,5-C]QUINOLIN-1-YL]PHENYL}PROPANENITRILE, 4-[2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4, 5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethylbenzeneacetonitrile, Benzeneacetonitrile, 4-(2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-

Name	Dactolisib
PubChem CID	11977753
Molecular Weight	469.5g/mol
Synonyms	dactolisib, 915019-65-7, NVP-BEZ235, BEZ235, NVP-BEZ 235, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile, BEZ-235, NVPBEZ235, BEZ 235, NVP-BEZ-235, NVP BEZ235, BEZ235 (NVP-BEZ235, Dactolisib), RTB101, RTB-101, RUJ6Z9Y0DT, NSC-751249, CHEBI:71952, 915019-65-7 (free base), 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, S1009, 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile, BEZ235 (NVP-BEZ235), NVP-BEZ235-NX, 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile., 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile, Dactolisib [USAN], Dactolisib [USAN:INN], UNII-RUJ6Z9Y0DT, 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile, Kinome_2911, CT-BEZ, Dactolisib (BEZ235), Dactolisib; BEZ-235, DACTOLISIB [INN], Dactolisib (USAN/INN), Nvp-bez235, free base, mTOR Inhibitor, BEZ235, DACTOLISIB [WHO-DD], NVP-BEZ235?, SCHEMBL143623, GTPL7950, CHEMBL1879463, BDBM92862, AMY2877, DTXSID10238599, EX-A404, BCPP000344, HMS3244G21, HMS3244G22, HMS3244H21, HMS3672E19, BCP00216, MFCD10565944, NSC751249, NSC755807, NSC800085, AKOS005217097, BCP9000397, CCG-207981, CS-0080, DB11651, ES-0038, NSC 751249, NSC-755807, NSC-800085, PB26555, 2-methyl-2-[3-methyl-2-oxo-8-(3-quinolinyl)-1-imidazo[4,5-c]quinolinyl]propanenitrile, Dactolisib (BEZ235, NVP-BEZ235), NCGC00187481-01, NCGC00187481-02, NCGC00187481-04, NCGC00187481-05, NCGC00187481-06, NCGC00187481-15, 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile, 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, AC-25486, HY-50673, FT-0658563, NS00071714, BEZ235 , NVP-BEZ235, EN300-60135, D10552, J-509915, Q4835503, BRD-K12184916-001-01-4, Z329731510, 1028385-31-0, 2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl)propionitrile, 2-Methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile, 2-methyl-2-[4-[3-methyl-2-oxo-8-(3-quinolyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile, 2-METHYL-2-{4-[3-METHYL-2-OXO-8-(QUINOLIN-3-YL)-1H,2H,3H-IMIDAZO[4,5-C]QUINOLIN-1-YL]PHENYL}PROPANENITRILE, 4-[2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4, 5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethylbenzeneacetonitrile, Benzeneacetonitrile, 4-(2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-
Drug Type	Small molecule
Formula	C₃₀H₂₃N₅O
SMILES	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
InChI	1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3
InChIKey	JOGKUKXHTYWRGZ-UHFFFAOYSA-N
CAS Number	915019-65-7
ChEMBL ID	CHEMBL1879463
ChEBI ID	CHEBI:71952
Drug Bank ID	DB11651
KEGG ID	D10552
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, Dactolisib
Partner Name	Curcumin
Disease Info	[ICD-11: 2D11]	Neuroblastoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP7	hsa840
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	SH-SY5Y	Neuroblastoma	Homo sapiens (Human)	CVCL_0019
Result	Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells.